Axsome Therapeutics Inc
AXSMLatest QuantConomy context for AXSM: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.
Axsome Therapeutics Inc
QuantConomy has a structured record for AXSM. More descriptive asset metadata will appear here when the platform record includes it.
- Symbol
- AXSM
- Name
- Axsome Therapeutics Inc
- Coverage
- 3 market/data records
- Sources
- alpaca fmp alphavantage sec nasdaq lse
Recent signals for AXSM
Scored rows are pulled from the same signal API used by the digests.
| Signal | Direction | Score | Observed | Reason |
|---|---|---|---|---|
| mixed activity | neutral | 61 | Jul 8, 02:00 PM | High smart money activity: 1 insider and 1 institutional signals for AXSM with mixed directions [moderate signal] |
| reduced position | bearish | 78 | Jul 8, 01:30 PM | Assenagon Asset Management S.A. reduced position in 0B7351 by 47.5% - 454,682 shares ($111.29M) - [strong bearish signal] |
| ten percent owner | slightly bullish | 55 | Jul 1, 11:35 PM | TABUTEAU HERRIOT (Chief Executive Officer, Director, 10% Owner) exercised options for AXSM shares ($0.25M) - 49,666 shares - [moderate slightly bullish signal] |
SMART_MONEY signals are experimental: they converge from institutional and insider activity, whose historical coverage is still being backfilled, so results may be sparse or empty.
EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).
Market coverage
| Market | Exchange | Source | Asset record |
|---|---|---|---|
| AXSM | NASDAQ | alpaca | Axsome Therapeutics, Inc. Common Stock |
| AXSM | NASDAQ | fmp | Axsome Therapeutics, Inc. |
| AXSM | NASDAQ | alphavantage | Axsome Therapeutics Inc |
Recent insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | exercise | 49,666 | $4.95 | $245,847 | 4 on EDGAR |
| Jun 10, 2026 | JEFFS ROGER | Director | sale | 286 | $246.18 | $70,407 | 4 on EDGAR |
| Jun 9, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | exercise | 49,670 | $4.95 | $245,867 | 4 on EDGAR |
| Jun 9, 2026 | Pizzie Nick | Chief Financial Officer | exercise | 33,000 | $3.50 | $115,500 | 4 on EDGAR |
| Jun 8, 2026 | Coleman Mark | Director | exercise | 1,429 | — | — | 4 on EDGAR |
| Jun 8, 2026 | Saad Mark E | Director | exercise | 1,429 | — | — | 4 on EDGAR |
| Jun 8, 2026 | JEFFS ROGER | Director | exercise | 1,429 | — | — | 4 on EDGAR |
| Jun 8, 2026 | Mahony Susan | Director | exercise | 1,429 | — | — | 4 on EDGAR |
| Jun 5, 2026 | Coleman Mark | Director | grant | 1,721 | — | — | 4 on EDGAR |
| Jun 5, 2026 | Saad Mark E | Director | grant | 1,721 | — | — | 4 on EDGAR |
| Jun 5, 2026 | JEFFS ROGER | Director | grant | 1,721 | — | — | 4 on EDGAR |
| Jun 5, 2026 | Mahony Susan | Director | grant | 1,721 | — | — | 4 on EDGAR |
| May 29, 2026 | Coleman Mark | Director | sale | 6,000 | $233.46 | $1,400,760 | 4 on EDGAR |
| May 4, 2026 | Jacobson Mark L. | Chief Operating Officer | exercise | 4,517 | $12.95 | $58,495 | 4 on EDGAR |
| Apr 22, 2026 | Maizel Ari | Chief Commercial Officer | exercise | 7,500 | $70.73 | $530,475 | 4 on EDGAR |
| Apr 21, 2026 | Maizel Ari | Chief Commercial Officer | grant | 7,224 | — | — | 4 on EDGAR |
| Apr 21, 2026 | Jacobson Mark L. | Chief Operating Officer | grant | 8,669 | — | — | 4 on EDGAR |
| Apr 21, 2026 | Murdock Hunter R. | General Counsel | grant | 7,224 | — | — | 4 on EDGAR |
| Apr 21, 2026 | Pizzie Nick | Chief Financial Officer | grant | 8,188 | — | — | 4 on EDGAR |
| Apr 21, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | grant | 24,081 | — | — | 4 on EDGAR |
Source: SEC filings via QuantConomy. Not investment advice.
Query AXSM context like a database.
These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.
More: All insider trades · How to read a Form 4 · API access